Docoh
Loading...
Sign up Log in

DXR Daxor

Daxor Corp. is a biotechnology company which develops and manufactures BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage; and andrology services, such as semen analysis, sperm washing and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in New York, NY.

Company profile

Ticker
DXR
Exchange
AMEX
Website
www.daxor.com
CEO
Michael R. Feldschuh
Employees
Incorporated
New York
Location
New York
Fiscal year end
Dec 31
Sector
Health Technology > Medical Specialties
Industry (SIC)
Surgical & Medical Instruments & Apparatus
3M • Boston Scientific • Baxter International • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences ...
SEC CIK
0000027367
Corporate docs
IRS number
132682108

DXR stock data

(
)

News

Pro users get this 30m faster
32 Stocks Moving in Friday's Pre-Market Session
23 Jul 21
Gainers Socket Mobile Inc (NASDAQ: SCKT) shares rose 100.2% to $11.61 in pre-market trading after the company reported better-than-expected Q2 results.
Daxor Announces Non-Government Distribution Agreement With Concordance Healthcare Solutions
22 Jul 21
Daxor Corporation (NYSE:DXR), the global leader in blood volume measurement technology, announces today that it has signed a non-government distribution agreement with Concordance Healthcare Solutions, one of the largest
64 Biggest Movers From Friday
7 Jun 21
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM System for up to 180 days. The Eversense CGM is a continuous glucose monitoring device.
Stocks That Hit 52-Week Lows On Thursday
13 May 21
Daxor Corporation Says Receives National Institutes Of Health Funding Notification For Landmark Multi-Center Heart Failures Trial Utilizing BVA-100 With U.S. Department Of Veterans Affairs
6 May 21

Press releases

Pro users get this 30m faster
Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021
28 May 21
NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxor's President and Chief Executive Officer
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
27 May 21
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual

Calendar

15 Mar 21
4 Aug 21
31 Dec 21

Recent insider trades

DXR insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
24 Jun 21 Henry D. Cremisi STOCK OPTION COMMON STOCK Grant Aquire A No No 10.82 2,000 21.64K 2,000
24 Jun 21 James A Lombard STOCK OPTION COMMON STOCK Grant Aquire A No No 10.82 2,100 22.72K 2,100
24 Jun 21 Joy S. Goudie STOCK OPTIONS COMMON STOCK Grant Aquire A No No 10.82 2,100 22.72K 2,100
24 Jun 21 Edward Feuer STOCK OPTION COMMON STOCK Grant Aquire A No No 10.82 2,100 22.72K 2,100
10 Jun 21 Robert J Michel Daxor Common Stock Grant Aquire A No No 0 2,000 0 6,250
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

DXR institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

5.2% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 8 9 -11.1%
Opened positions 1 6 -83.3%
Closed positions 2 0 NEW
Increased positions 3 2 +50.0%
Reduced positions 3 0 NEW
13F shares
 Current Prev Q Change
Total value 2.55M 3.05M -16.3%
Total shares 204.05K 193.49K +5.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
Sabby Management 128.4K $1.61M +4.9%
Vanguard 47.33K $592K +31.0%
Renaissance Technologies 25.52K $319K -13.5%
UBS UBS Group AG - Registered Shares 1.31K $16K +74.4%
Tower Research Capital 982 $12K -0.6%
WFC Wells Fargo & Co. 288 $4K 0.0%
MS Morgan Stanley 175 $2K NEW
Advisory Services Network 50 $1K -75.0%
Proequities 0 $0
Largest transactions
 Shares Bought/sold Change
Vanguard 47.33K +11.19K +31.0%
Sabby Management 128.4K +5.99K +4.9%
Renaissance Technologies 25.52K -4K -13.5%
Advisor 0 -3.19K EXIT
UBS UBS Group AG - Registered Shares 1.31K +559 +74.4%
MS Morgan Stanley 175 +175 NEW
Advisory Services Network 50 -150 -75.0%
Tower Research Capital 982 -6 -0.6%
BAC Bank Of America 0 -1 EXIT
WFC Wells Fargo & Co. 288 0 0.0%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial reports

View all
N-CEN
Annual report (registered investment company)
15 Mar 21
N-CSR
Certified annual shareholder report (management investment company)
25 Feb 21
N-CSRS
Certified semi-annual shareholder report (management investment company)
21 Aug 20
N-CEN
Annual report (registered investment company)
13 Mar 20
N-CSR
Certified annual shareholder report (management investment company)
28 Feb 20
N-CSRS
Certified semi-annual shareholder report (management investment company)
27 Aug 19
N-CEN/A
Annual report (registered investment company) (amended)
23 May 19
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
22 May 19
N-CEN
Annual report (registered investment company)
17 Mar 19
N-CSR
Certified annual shareholder report (management investment company)
1 Mar 19

Current reports

View all
8-K
Submission of Matters to a Vote of Security Holders
30 Jun 21
8-K
Other Events
6 May 21
8-K
Breakthrough Patent-pending Tracer Developed for Broad Use
15 Mar 21
8-K
Other Events
5 Oct 20
8-K
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering
21 Jul 20
8-K
Daxor Announces Prospective Randomized Control Trial at Duke University Medical Center to Guide Volume Treatment In Heart Failure Patients
16 Jul 20
8-K
Daxor Announces Initiation of First-of-It’s-Kind Multicenter BVA-100® Study in Hospitalized Patients with COVID-19
15 Jul 20
8-K
Daxor Corporation Announces Appointment of Henry D. Cremisi, MD, FACP and Joy Goudie, Esq. to the Company’s Board of Directors
1 Jul 20
8-K
Other Events
6 May 20
8-K
Other Events
23 Apr 20

Registration and prospectus

S-8
Registration of securities for employees
16 Sep 20
POS EX
Additional exhibits for listing
31 Oct 18
RW
Registration withdrawal request
9 May 13
S-8
Registration of securities for employees
5 Jul 04
S-3
Shelf registration
17 Mar 98

Proxies

View all
DEF 14A
Definitive proxy
2 Jun 21
N-PX
Annual report of proxy voting record
31 Aug 20
DEF 14A
Definitive proxy
4 Jun 20
N-PX
Annual report of proxy voting record
30 Aug 19
DEFR14A
Revised proxy
2 Jun 19
DEF 14A
Definitive proxy
30 May 19
N-PX
Annual report of proxy voting record
10 Jul 18
N-PX/A
Annual report of proxy voting record (amended)
12 Jun 18
DEF 14A
Definitive proxy
22 May 18
DEF 14A
Definitive proxy
13 Nov 17

Other

View all
EFFECT
Notice of effectiveness
19 Jul 21
EFFECT
Notice of effectiveness
15 Jul 20
CORRESP
Correspondence with SEC
12 Jul 20
EFFECT
Notice of effectiveness
23 May 19
CORRESP
Correspondence with SEC
19 May 19
CORRESP
Correspondence with SEC
16 May 19
CORRESP
Correspondence with SEC
9 May 19
CORRESP
Correspondence with SEC
9 May 19
CORRESP
Correspondence with SEC
2 May 19
CORRESP
Correspondence with SEC
2 Apr 19

Ownership

View all
4
DAXOR / Edward Feuer ownership change
28 Jun 21
4
DAXOR / Joy S. Goudie ownership change
28 Jun 21
4
DAXOR / JAMES A LOMBARD ownership change
28 Jun 21
4
DAXOR / Henry D. Cremisi ownership change
28 Jun 21
4
DAXOR / Robert J Michel ownership change
14 Jun 21
NPORT-P
None (Mar 2021 report)
13 May 21
4
DAXOR / Robert J Michel ownership change
19 Apr 21
4
DAXOR / Michael Richard Feldschuh ownership change
16 Apr 21
NPORT-P
None (Sep 2020 report)
21 Oct 20
4
DAXOR / of Joseph Feldschuh Estate ownership change
3 Aug 20

Patents

APP
Utility
Remote Blood Volume Monitor
23 Sep 20
Systems and methods are disclosed for providing ongoing monitoring and updating of blood volume status, where the system or method can include guidance in the form of recommendations for treatment actions or alerts about altered patient status.
APP
Utility
Flow-through Quantitative Blood Collection Vial
29 Apr 20
A device is presented for storing, transporting, measuring, and collecting blood, having the properties of a precisely determined volume, the ability to be emptied or filled while connected to a continuous source (such as a supply of a drug, or the bloodstream of a patient), and a geometry suitable for the entire device to be placed in the counting chamber of a detector (such as the counting well of a gamma counter).
APP
Utility
Blood Volume Analyzer with Guidance
29 Apr 20
Systems and methods are provided for analyzing blood of a living being, and for presenting guidance for medical treatment.
APP
Utility
Whole Blood Volume Analyzer
29 Apr 20
Systems and methods are provided for measuring blood volume of a living being.

Reddit threads

Pro users get this 30m faster